Poster Abstract Session:
177. Clinical Trials
Saturday, October 5, 2013: 12:30 PM-2:00 PM
Room: The Moscone Center: Poster Hall C

Tracks: Adult ID


Comparison of Early Achievement of >20% Reduction in Lesion Size of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) between Patients who Received Oritavancin or Vancomycin in SOLO 1
Kenneth T. Lapensee, Ph.D., M.P.H. ; Thomas Lodise, PharmD ; Norman Huang, MD ; Hai Jiang, PhD ; Weihong Fan, MS ; Mike Mcguire
  • IDSA 2013 poster v01c.pdf (392.5 kB)

  • Fluconazole and MGCD290 in vulvo vaginal candidiasis (VVC):  Results from a randomized phase II study
    Michael Augenbraun, MD, FACP ; Jeff Livingston, MD ; Robert Parker, MD ; Samuel Lederman, MD ; Steven Chavoustie, MD ; Franklin Morgan, MD ; Gregory Reid, MSc ; Laura Pearce ; Rachel Humphrey, MD ; Jeffrey Besterman, PhD ; Jack Sobel, MD, FIDSA

    What Research do Clinicians Want? A survey of Infectious Diseases Physicians
    Tiffany M. Brown, BSN RN, MPH ; David L. Paterson, MD PhD
  • IDweekposter.pdf (417.5 kB)

  • An Analysis of the Safety Profile of Dalbavancin from the Phase 2/3 Clinical Program
    Michael Dunne, MD ; Anita Das, PhD ; Sailaja Puttagunta, MD
  • ISS_Poster_FINAL_IDSA.pdf (77.8 kB)

  • Fluconazole or Posaconazole in Antifungal prophylaxis in Patients with High-Risk Hematological Malignity?
    Selçuk Kaya, Asisstant Professor ; Iftihar Köksal, Professor ; Eda Gençalioglu ; Mehmet Sönmez, Professor ; Mustafa Yılmaz, Associate Professor ; Gürdal Yılmaz, Associate Professor
  • IDW poster.pdf (116.0 kB)

  • Synergistic, Meltable Antimicrobial Wrap for Reducing Tissue Expander Infections in patient with breast reconstruction
    Joel Rosenblatt, PhD ; Ray Hachem, MD ; Ruth Reitzel, MS ; George M. Viola, MD, MPH ; Issam Raad, MD

    Microbiologic Analyses of Target Pathogens Identified in the Dalbavancin DISCOVER Program
    Michael Dunne, MD ; Helen Boucher, MD, FIDSA ; Mark Wilcox, MD ; Sailaja Puttagunta, MD ; George Talbot, MD
  • 9-25_Micro_Poster_IDSA.pdf (87.7 kB)

  • An Integrated Analysis of the Efficacy of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (abSSSI) from the DISCOVER Program
    Mark Wilcox, MD ; Helen Boucher, MD, FIDSA ; George Talbot, MD ; Anita Das, PhD ; Sailaja Puttagunta, MD ; Michael Dunne, MD

    Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum from Unrelated Donors – a Randomized, Open Label, Controlled Pilot Study
    Ilan Youngster, M.D. ; Jenny Sauk, M.D. ; Christina Pindar ; George Russell, M.D. ; Elizabeth Hohmann, MD ; Jess Kaplan, M.D.

  • Poster 1 USA.pdf (1.2 MB)

  • Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in adolescents
    Xavier Saez-Llorens, MD ; Maria-Gabriela Grana, MD ; Esther Heijinen, MD ; Igor Smolenov, MD ; Peter Dull, MD
  • 1348_IDW Poster.pdf (657.1 kB)

  • Pilot Trial of Bacterial Interference in Patients with Indwelling Catheters
    Barbara W. Trautner, MD, PhD ; Deborah Horwitz, MS, PA-C
  • Slide1.PNG (419.0 kB)

    Mayar Al Mohajer, MD ; Danish Siddiq, MD ; Charles Minard, PhD ; Rabih Darouiche, MD

    Use of Antimicrobial Central Venous Catheters for Exchange Over Guidewire in Staphylococcus aureus Central Line Associated Bloodstream Infection
    Aline El Zakhem, MD ; Anne-Marie Chaftari, MD ; Ray Hachem, MD ; Ying Jiang, MS ; Issam Raad, MD

    Use of an Antibiotic-Probiotic Combination to Treat Recurrent Urinary Tract Infections: A Pediatric Case-series
    Mehreen Arshad, MD ; Ramiro Madden-Fuentes, MD ; Sherry Ross, MD ; Patrick Seed, MD, PhD

    Cytomegalovirus Disease in Patients with Hematological Malignancies: Identifying Risk Factors
    Mona Alfares, MD ; Susan Szpunar, PhD ; Mary Mandziara, MSN, ACNP-BC, AOCN ; Kleanthe Kolizeras, BS ; Ayad al-Katib, M.D. ; Karam Obeid, MD
  • CMVposterfinal.pdf (159.6 kB)

  • Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) In Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) Or Boceprevir (BOC)
    Mark Sulkowski, MD ; David Gardiner ; Maribel Rodriguez-Torres, MD ; K. Rajender Reddy, MD ; Tarek Hassanein, MD ; Ira Jacobson, MD ; Eric Lawitz ; Anna S.F. Lok, MD, FRCP ; Federico Hinestrosa ; Paul J. Thuluvath ; Howard Schwartz ; David Nelson ; Gregory T. Everson ; Timothy Eley, PhD ; Megan Wind-Rotolo ; Shu-Pang Huang ; Min Gao ; Fiona Mcphee ; Dennis Hernandez ; Diane Sherman ; Robert Hindes ; William Symonds, PharmD ; Claudio Pasquinelli ; Dennis Grasela, PharmD, PhD

    CME Credits:

    ACPE Credits:

    ACPE Number:

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.